chance is there...

needed to wait & see how...

This ipo has big OFC..normally OFC will not bring extra cash to company because it only involves existing shareholders..what the company will get is only the new public issue..offer for sale (ofc) involves change of existing shares ownership i.e existing shareholders get money from the sale of their shares..company already got the money before..a bit confuse about this IPO

Wonder why biz so good why want offer for sell?

another senheng  ?

ticket 5000 

Wonder why biz so good why want offer for sell?

ticket 5000 

ticket 5000 

Ipo from medical line normally gives profit...

The Dragon Amongst ACE Market IPO - Alpha IVF

Entering 2024, Alpha IVF Group Berhad is emerging as a noteworthy company, poised to make its debut on the stock market. This development is not just another IPO; it signifies the entry of Malaysia’s second company, after another listed on the LEAP market, to specialize in assisted reproductive services. With a focus on providing hope to couples facing infertility challenges, Alpha IVF stands out for its advanced in vitro fertilization (IVF) and other reproductive technologies.

Rumors suggest that Alpha IVF’s post-IPO valuation could fetch over RM1.0 billion, potentially marking it as one of the largest IPOs in the ACE market segment in recent years. Such anticipation is fueled by the company’s impressive financial performance, with Profit After Tax (PAT) margins showing substantial growth over recent fiscal periods, highlighting the company’s operational efficiency and profitability.

Alpha IVF’s financial resilience is evident from its escalating PAT margins, which have outperformed many in the tech sector. With figures rising from 3.71% in FYE2021 to an astonishing 43.59% in FPE2023 (9 months), the company’s profitability trajectory is impressive. However, the sustainability of these margins remains a focal point of interest as the official prospectus is awaited, with many fund managers keenly observing.

Post-IPO, Alpha IVF intends to uphold a generous dividend payout ratio of 60.0%, promising a substantial return to its shareholders. This strategy underscores the company’s confidence in its cash-generative business model, which relies more on expertise than on heavy asset investments. Furthermore, Alpha IVF’s expansion plans include extending its footprint to Indonesia and potentially Cambodia or Laos, alongside establishing a sales center in China to tap into the burgeoning medical tourism sector.

At the heart of Alpha IVF’s success is its comprehensive approach to understanding and addressing the unique needs of its clients. From assessing sperm and ova health to pioneering techniques in ovarian stimulation and cryopreservation, the company stands at the forefront of reproductive technology. Alpha IVF’s services extend beyond traditional IVF, incorporating advanced procedures like Preimplantation Genetic Testing (PGT) to enhance success rates and reduce genetic risks.

In an era where technology intersects with healthcare, Alpha IVF leverages AI to select embryos with higher chances of successful implantation, further refining its service offerings. The company also explores innovative treatments like Ova-PRP to improve ovarian health, showcasing its commitment to advancing reproductive technologies.

With declining birth rates and changing societal attitudes towards parenthood, IVF services like those offered by Alpha IVF may become increasingly sought after, presenting a compelling narrative for investors and industry observers alike.

dont play play lah, another IPO addict?

money man...kenot play play nanti rugi
cry till ah mah pon kenot regonised
ini ipo got many conrnerstone support
Mercury pon kasi predict 0.37 cts
untung 5 cts is more than 10% better than EPF only 5.5%
u tak mau beli meh...
now ipo very very hard to make money
tis one got 5 cts untung is consider money drop from sky